sh-Oligopeptide-9 for Hair Regrowth

Evidence Review created on 09/27/2026 using AI4L + evidence-mcp / GPT 6

Also known as: Oligopeptide-9

Motivation

sh-Oligopeptide-9 is a laboratory-produced cosmetic ingredient related to natural chemical messengers in the skin. Interest in its possible use for hair regrowth comes from research into how chemical signals in skin influence hair roots, cell renewal, and local inflammation. For adults interested in maintaining appearance and quality of life across a longer lifespan, hair preservation can be a meaningful goal alongside broader health priorities.

Peptides appear in many skin and scalp formulations, sometimes alongside other active ingredients and procedures. Similar ingredient names can obscure substantial biological differences. In particular, sh-Oligopeptide-9 and sh-Polypeptide-9 are separate ingredients, despite their shared number. Research on naturally occurring skin signals, laboratory compounds that act on the cells receiving those signals, and finished cosmetic mixtures also asks different questions from research on this particular ingredient applied to the scalp.

This review examines the identity of sh-Oligopeptide-9, the relevance of available research to hair regrowth, and the evidence concerning benefits, risks, formulation, and practical use. It separates changes in hair growth from changes in scalp condition and examines how outcomes could be documented over time.

Benefits - Risks - Protocol - Conclusion

These original studies explain the related skin-signaling biology and the limits of transferring it to a cosmetic ingredient.

Only three sources met the relevance criteria without adding general hair-loss material. No directly relevant item from the six priority platforms was verified; Life Extension’s on-site search remained inaccessible, so its coverage could not be conclusively assessed.

Grokipedia

No dedicated Grokipedia article for sh-Oligopeptide-9 was found in the direct search as of September 27, 2026.

Examine

No Examine article for sh-Oligopeptide-9 was found as of September 27, 2026.

ConsumerLab

No dedicated ConsumerLab article for sh-Oligopeptide-9 was found as of September 27, 2026.

Systematic Reviews

No systematic reviews or meta-analyses for Sh-Oligopeptide-9 were found on PubMed as of September 27, 2026.

Mechanism of Action

The Korea Cosmetic Association ingredient entry identifies sh-Oligopeptide-9 as an enkephalin-associated recombinant peptide (produced using an engineered gene), made through Escherichia coli fermentation. The association represents cosmetic businesses that earn revenue from ingredient-containing products; its entry documents naming and cosmetic functions, not clinical efficacy. Its description mentions both 11 amino acids and a precursor of up to 267 residues, so it does not securely establish a finished product’s exact active sequence.

Natural enkephalins occur in the outer sheath of human hair follicles, according to Slominski et al.. Related receptor activation offers a possible growth mechanism: Zheng et al. linked a different compound, UFP-512, to Wnt/β-catenin signaling (a cell-communication pathway controlling growth and renewal). Conversely, Zagon et al. found that methionine-enkephalin restrained skin-cell replication in laboratory models. Different molecules, receptors, and tissues explain why these are competing mechanistic possibilities, rather than conflicting clinical trials.

For sh-Oligopeptide-9 itself, receptor selectivity, effective follicle exposure, human half-life, systemic distribution, and metabolism have not been established in the retrieved literature. Peptide breakdown by protein-cleaving enzymes is plausible, but no specific enzyme pathway or human elimination rate is demonstrated. Skin penetration and formulation stability remain unmeasured prerequisites; natural signaling does not establish benefit from external application.

Historical Context & Evolution

The documented starting point is cosmetic skin conditioning and protection, rather than an established hair-loss medicine. The Korea Cosmetic Association, whose members sell cosmetic products, records a 2009 name change from Oligopeptide-9 to sh-Oligopeptide-9 in its ingredient dictionary. This is a nomenclature milestone, not proof of when the ingredient was invented or first used clinically.

The related research developed along distinct lines. In 1996, Zagon and colleagues demonstrated inhibitory effects of methionine-enkephalin on skin-cell replication. In 2011, Slominski and colleagues showed regulated production of enkephalins in human skin, including structures surrounding hair roots. These findings made local signaling biologically credible without demonstrating regrowth from a cosmetic product.

In 2021, Zheng and colleagues reported growth-related effects of a selective opioid-receptor activator in experimental models. That advanced a therapeutic hypothesis while leaving ingredient equivalence and human efficacy unresolved. Separately, Bassino and colleagues’ 2016 paper concerns sh-Polypeptide-9, a different peptide associated with vascular endothelial growth factor (a signal involved in blood-vessel formation). One author lists a pharmaceutical-company affiliation. Its similar name does not make it evidence for sh-Oligopeptide-9. Current interest therefore combines a cosmetic naming history with adjacent biological research, rather than a demonstrated progression into a validated hair-regrowth treatment.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: replicated human hair-regrowth or scalp-symptom trials of sh-Oligopeptide-9 were not identified.

Medium 🟩 🟩

No benefit reaches Medium: no single controlled human outcome trial or consistent observational outcome study of the ingredient was identified.

Low 🟩

Speculative 🟨

Hair regrowth

Related opioid-receptor activation promoted experimental hair growth using a different compound, UFP-512. This is a mechanistic hypothesis for sh-Oligopeptide-9, with no demonstrated human regrowth, density, thickness, or shedding benefit.

Improved scalp comfort ⭕️ Not Central to Hair Regrowth

Natural enkephalin production can restrain experimental skin inflammation through nerve–immune signaling, as Mendoza et al. describe. Whether externally applied sh-Oligopeptide-9 relieves scalp symptoms or indirectly supports hair growth remains untested.

Skin hydration and conditioning ⭕️ Not Central to Hair Regrowth

The listed cosmetic functions concern skin protection and conditioning; the association’s members sell cosmetic products. This classification does not establish measured hydration or regrowth benefits.

Benefit-Modifying Factors

  • Ingredient and delivery: Sequence, concentration, stability, formulation base, and intact follicle exposure could determine biological activity. No effective exposure threshold is established, and a finished serum’s results cannot identify the contribution of this one ingredient.
  • Hair-loss cause: Pattern hair loss, temporary shedding, and inflammatory or scarring disorders are different targets. No direct efficacy evidence identifies a responsive diagnosis; regrowth after destruction of follicles has not been demonstrated.
  • Genetics: No genetic variant predicts response to sh-Oligopeptide-9. Associations involving other opioid-system traits do not establish a useful hair-treatment test.
  • Baseline biomarkers: No blood or scalp biomarker selects likely responders. Nutrient deficiency or thyroid disease may explain hair loss independently; correcting those conditions would confound attribution to the peptide.
  • Sex: No direct comparison establishes different benefits in men and women. Findings in male mice cannot determine efficacy in either human group.
  • Age: No age-specific response estimates exist, including for older adults. Hair-loss duration and remaining viable follicles are relevant context, but have not been validated as predictors for this ingredient.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: replicated human adverse-event studies of sh-Oligopeptide-9 were not identified.

Medium 🟥 🟥

No risk reaches Medium: a direct human trial or consistent observational safety dataset for the ingredient was not identified.

Low 🟥

Speculative 🟨

Scalp irritation or allergy

The peptide, preservatives, or other formulation ingredients could provoke redness, burning, itching, or allergy. This is a general topical-product possibility; no ingredient-specific human incidence or sensitization study was identified.

Unfavorable effects on hair growth

Methionine-enkephalin inhibited skin-cell replication in experimental research. This mechanistic observation raises uncertainty about growth direction; it does not demonstrate hair loss from sh-Oligopeptide-9.

Infection or tissue injury with invasive delivery

Injecting or microneedling cosmetic formulations could introduce contaminants and injure skin. This route-related concern is inferred from barrier disruption; it is not a documented adverse-event rate for topical sh-Oligopeptide-9.

Unintended effects beyond the scalp

Systemic absorption and receptor activity of formulated sh-Oligopeptide-9 are unknown. Nerve–immune effects are mechanistically conceivable, but sedation, dependence, hormone disruption, and cancer risk have not been demonstrated for this ingredient.

Risk-Modifying Factors

  • Skin integrity: Inflamed, infected, scratched, or recently needled skin changes the exposure context and could increase irritation or contamination risk. No safe waiting interval after procedures has been established for this peptide.
  • Existing sensitivities: A previous reaction to the peptide or any formulation ingredient increases concern about re-exposure. Full-formula composition matters more than an isolated ingredient label.
  • Genetics: No validated genetic risk marker exists. Opioid-system genetic associations from other drugs cannot quantify cosmetic-peptide risk.
  • Baseline biomarkers: No laboratory concentration predicts toxicity or defines safe exposure. Abnormal results warrant interpretation in their own clinical context, not peptide-specific dose adjustments.
  • Sex and reproduction: Sex-specific adverse-event data and pregnancy or lactation exposure data are absent. This is uncertainty, not demonstrated reproductive toxicity.
  • Age and health: Older adults and people with fragile skin, impaired healing, or major organ disease have no characterized safety profile. No age cutoff or kidney/liver dose-adjustment rule is established.

Key Interactions & Contraindications

No established ingredient-specific interaction or contraindication monograph was found. The following distinctions describe uncertainty and general formulation risks rather than validated prescribing rules.

  • Prescription receptor blockers (naltrexone, naloxone) — theoretical caution: These drugs might alter an opioid-mediated effect if one occurs. Clinical relevance is unknown; no dose change or timing separation is supported. The hypothesis comes from related experimental signaling.
  • Topical medications — caution: Minoxidil, tretinoin, and ketoconazole formulations can complicate attribution of scalp irritation or improvement. No sh-Oligopeptide-9 combination study establishes benefit, harm, compatible mixing, or a protective application interval.
  • Nonprescription products — caution: Exfoliating acids and alcohol-rich scalp products could add irritation. Separate introduction of products helps identify reactions; no specific spacing interval has been tested for this peptide.
  • Supplements — unknown: No interaction or additive benefit is established with biotin, iron, zinc, collagen, or saw palmetto. This absence of data does not establish compatibility; no supplement timing or dose modification is supported.
  • Procedures — caution: Microneedling, injections, and application immediately after transplantation alter barrier exposure and could increase injury or contamination. Keeping cosmetic formulations within their labeled route avoids this untested exposure; no validated needle depth or procedural dose exists.

Populations who should avoid Sh-Oligopeptide-9:

  • Known product allergy: People with a documented allergy to an ingredient in the formulation; avoidance concerns recurrence of the reaction.
  • Pregnancy or lactation: Precautionary exclusion for elective hair-regrowth use because exposure and reproductive safety are unstudied; not evidence of birth-defect risk.
  • Children: No pediatric hair-regrowth efficacy, dosing, or safety evidence was found.
  • Active scalp infection or open wounds: Precaution applies to application at the affected site and especially invasive use; no validated severity threshold establishes safety.

Risk Mitigation Strategies

  • Verify identity: Checking the exact ingredient name, sequence documentation, and full formula prevents substitution of sh-Polypeptide-9 and inappropriate reliance on another peptide’s research.
  • Limit route: Restricting a cosmetic formulation to its labeled topical route avoids introducing nonsterile material through injections or needling. Cosmetic labeling supplies no evidence for invasive dosing.
  • Track tolerability: Documenting redness, burning, itching, and swelling from the first application helps identify reactions. Discontinuation and assessment of persistent or marked symptoms limit continued exposure; no validated peptide-specific symptom threshold exists.
  • Reduce attribution errors: Introducing only one new scalp product at a time and recording other treatments helps distinguish formulation irritation from unrelated changes. No tested washout interval is available.
  • Preserve diagnostic clarity: Recording the cause and pattern of hair loss before experimentation reduces the risk of attributing ongoing disease or temporary shedding to a cosmetic response.

Therapeutic Protocol

  • Established regimen: No validated therapeutic protocol, effective concentration, volume per scalp area, treatment duration, or leading-practitioner regimen for sh-Oligopeptide-9 was identified. A numerical regimen would be an invention.
  • Topical formulations: Product directions describe the whole cosmetic formulation. They cannot establish an effective peptide dose or demonstrate that another formulation provides equivalent exposure.
  • Alternative approaches: Topical use and delivery with needling or injections are different exposures. No comparative evidence identifies an optimal approach; protocols for other peptides or growth-factor mixtures do not transfer.
  • Timing and frequency: No evidence favors morning or evening, single versus repeated daily application, or timing relative to washing. Human half-life is unknown, so frequency cannot be inferred from how quickly the body clears the peptide.
  • Genetics and biomarkers: No genetic test, blood result, or scalp measurement has a validated role in selecting a peptide dose. Testing for causes of hair loss is a separate diagnostic process.
  • Sex and age: No sex-specific or age-specific regimen exists, including for older adults. Animal concentrations do not define human dosing.
  • Underlying conditions: Scarring, active inflammation, infection, and systemic causes of shedding require separate characterization. No condition-specific response or dose-adjustment evidence exists for this ingredient.

Discontinuation & Cycling

  • Duration: Neither a short course nor lifelong maintenance has been validated. Durability after stopping and the need for continued exposure are unknown.
  • Withdrawal: No ingredient-specific withdrawal or rebound study was identified. Natural opioid signaling does not establish dependence, and absence of reports does not prove stopping has no effect.
  • Tapering: No evidence-based taper exists. Decisions about stopping other active ingredients in the same product depend on those ingredients, not on sh-Oligopeptide-9 evidence.
  • Cycling: No on/off schedule has demonstrated preserved efficacy or lower risk. Drug holidays cannot be justified from an unknown human half-life.

Sourcing and Quality

  • Identity: Exact standardized name and sequence documentation matter. Enkephalin-related terminology does not prove equivalence to a particular natural enkephalin, while sh-Polypeptide-9 is a separate ingredient.
  • Concentration and purity: Batch-specific independent identity, concentration, impurity, and microbiological testing would reduce uncertainty about exposure and contamination. An ingredient list alone provides neither potency nor an effective dose.
  • Stability: Finished-product stability, storage conditions, expiration, and delivery data are more informative than raw-peptide purity alone. Encapsulation or specialized packaging does not itself demonstrate follicle penetration or regrowth.
  • Supply channels: No brand or compounding pharmacy has been independently validated for sh-Oligopeptide-9 hair regrowth in the retrieved evidence. “Research use” labeling does not establish suitability for human application.
  • Route standards: Cosmetic microbial testing and pharmaceutical sterility testing answer different questions. A topical ingredient listing does not establish suitability for injection or application through disrupted skin.

Practical Considerations

  • Time to effect: No observed time to regrowth is available for sh-Oligopeptide-9. Assessments over months can document hair changes, but a proposed follow-up interval is not evidence of when this peptide works.
  • Common pitfalls: Confusing oligopeptide with polypeptide, equating smoother hair with new growth, crediting a mixture’s effects to one component, and changing several treatments together can all create misleading impressions.
  • Regulatory status: No hair-regrowth authorization for this ingredient was identified. Under the United States cosmetic–drug distinction, claims to restore hair growth establish drug intent; cosmetic availability is not approval of that claim.
  • Cost and access: Products and concentrations are not standardized, preventing a meaningful treatment-cost estimate. Unspecified concentrations also prevent comparing cost per effective dose; no effective dose is known.
  • Health and longevity: No evidence establishes effects on lifespan or broader health outcomes. Here the relevant potential value is hair appearance and scalp comfort, with effectiveness still unmeasured.

Interaction with Foundational Habits

  • Sleep: No direct benefit, disruption, or interaction has been demonstrated. The ingredient’s relationship to natural opioid signaling does not establish a sedative effect; there is no evidence-based bedtime schedule.
  • Nutrition: No direct interaction or nutrient depletion is established. Nutritional causes of shedding are independent factors; neither extra protein nor supplements have been shown to strengthen this peptide’s effect.
  • Exercise: No direct effect on training adaptation or recovery is established. Sweating and washing may alter how long a topical formulation stays on skin, but no exercise-related application interval has been tested.
  • Stress management: An indirect relationship is biologically plausible because skin enkephalin production responds to stress signals in human-tissue research. No study shows that stress reduction increases this ingredient’s effect, or that the ingredient improves psychological stress.

Monitoring Protocol & Defining Success

Baseline documentation covers the hair-loss diagnosis, duration, current treatments, scalp condition, and standardized photographs. Magnified imaging of a fixed scalp area improves reproducibility. Laboratory testing addresses suspected causes of hair loss; no peptide-specific safety panel or functional target is validated.

Symptoms can be recorded during week one and week four, with matched photographs and hair measurements at three and six months. These proposed intervals document changes rather than establish a treatment schedule. Success means sustained visible improvement supported by measurements without unacceptable symptoms. No minimum meaningful change is established. Stable background treatments, lighting, hair length, and measurement sites reduce misattribution but cannot establish causality.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Hair density in a fixed scalp area No established target; track hairs/cm² against individual baseline Quantify change Same site and imaging method at baseline, three and six months; no fasting requirement
Hair-shaft diameter No established target; track change from individual baseline Assess thickness Same instrument and sampling region; distinguish from temporary cosmetic coating
Ferritin, when deficiency is suspected No established peptide-specific functional target; track deficiency and its correction Identify alternative cause Ferritin reflects iron stores and can rise with inflammation; interpret with clinical context, not a universal hair-regrowth cutoff
Thyroid-stimulating hormone, when indicated No established peptide-response target; track an identified thyroid disorder Identify alternative cause Interpreted with symptoms and laboratory-specific ranges; routine serial testing is not supported solely by peptide use

Qualitative outcomes:

  • Appearance: Satisfaction with coverage.
  • Tolerability: Dated itching, burning, tenderness, redness, scaling, or swelling.
  • Shedding: Sustained changes, considering illness, stress, and other treatments.

Emerging Research

  • Direct clinical development: No registered trial specifically evaluating sh-Oligopeptide-9 for hair regrowth was found in ClinicalTrials.gov searches as of September 27, 2026. There is therefore no verified participant count, phase, endpoint, or ongoing trial identifier to report.
  • Potential growth signal: Zheng et al., 2021 provide a rationale for testing receptor-targeted hair treatments. A chemically verified sh-Oligopeptide-9 preparation could support that hypothesis if it reproduces relevant effects at achievable scalp exposure; the existing study does not establish this equivalence.
  • Potential unfavorable signal: Zagon et al., 1996 make reduced skin-cell replication a relevant competing hypothesis. Testing actual formulations in hair-follicle systems could weaken the case if growth is inhibited, or show that this mechanism does not apply.
  • Scalp inflammation: Mendoza et al., 2025 identify a local enkephalin–immune mechanism. Translating the body’s own signaling into an applied peptide effect remains uncertain; improved symptoms would still be a different endpoint from hair regrowth.
  • Decisive study design: Sequence and stability verification, human skin-exposure measurements, and a blinded comparison with an otherwise identical peptide-free formulation could separate ingredient effects from formulation effects. Both null and unfavorable results would materially affect its value for sustained personal use.

Conclusion

sh-Oligopeptide-9 is a laboratory-produced cosmetic ingredient related to natural chemical messengers in skin. Its proposed relevance to hair regrowth rests on research showing that these messengers occur around hair roots and that related signals can influence cell behavior. That biological connection has not established that applying this particular ingredient improves hair density, thickness, shedding, or visible coverage in people.

The direction of any effect also remains uncertain. Related experimental findings include both growth-promoting signals and reduced skin-cell division, using different molecules and settings. Proposed improvements in scalp comfort or skin condition remain separate from demonstrated regrowth. Safety is similarly uncertain: irritation and reactions to the finished product are plausible, while entry into the bloodstream, long-term effects, and consequences of injections or needling lack direct evidence.

Commercial interests affect parts of the information base: the ingredient dictionary comes from a trade association whose members sell cosmetic products, and relevant laboratory papers include company-affiliated authors. Neither source establishes clinical effectiveness. For adults prepared to invest time and effort in preserving hair, the current evidence does not quantify a benefit that can be weighed against those commitments. Exact ingredient identity, product composition, and clear documentation of outcomes dominate the practical assessment; no established effective dose or continued-use schedule closes these gaps.

Top - Benefits - Risks - Protocol